CDKN2D polyclonal, anti-human
€388.00
In stock
SKU
BS6940
Background:
The normal progression of cells through the cell cycle is under the control of the cyclin dependent protein kinases Cdk4 and Cdk6, which are subject to inhibition by the mitotic inhibitory protein, p16. Isolated members of the p16 family have been designated p15, p18 and p19. p15 expression is upregulated approximately 30-fold in TGF ß-treated human keratinocytes, suggesting that p15 may function as an effector of TGF ß-mediated cell cycle arrest through inhibition of Cdk4 and Cdk6 kinases. The gene encoding p15 has been mapped to chromosome 9p21.3 at a position adjacent to the p16 gene, at a site of frequent chromosomal abnormality in human tumors. Two p16- related proteins, p19 and p18, specifically inhibit the kinase activities of Cdk4 and Cdk6 but do not affect those of cyclin E-Cdk2, cyclin A-Cdk2 or cyclin B-Cdc2 complexes. p19 is expressed at maximal level during S phase, while overexpression of p19 leads to G1 arrest.
Alternative Name:
Cyclin-dependent kinase 4 inhibitor D, p19-INK4d, CDKN2D
Application Dilution: WB: 1:500~1:2000, IF: 1:50~1:200
Specificity: CDKN2D polyclonal antibody detects endogenous levels of CDKN2D protein.
Immunogen:
Recombinant full length Human CDKN2D.
MW: ~ 18 kDa
Swis Prot.: P55273
Purification & Purity:
The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen and the purity is > 95% (by SDS-PAGE).
Format:
1mg/ml in PBS with 0.1% Sodium Azide, 50% Glycerol.
Storage:
Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze-thaw cycles.
For research use only, not for use in diagnostic procedure.
The normal progression of cells through the cell cycle is under the control of the cyclin dependent protein kinases Cdk4 and Cdk6, which are subject to inhibition by the mitotic inhibitory protein, p16. Isolated members of the p16 family have been designated p15, p18 and p19. p15 expression is upregulated approximately 30-fold in TGF ß-treated human keratinocytes, suggesting that p15 may function as an effector of TGF ß-mediated cell cycle arrest through inhibition of Cdk4 and Cdk6 kinases. The gene encoding p15 has been mapped to chromosome 9p21.3 at a position adjacent to the p16 gene, at a site of frequent chromosomal abnormality in human tumors. Two p16- related proteins, p19 and p18, specifically inhibit the kinase activities of Cdk4 and Cdk6 but do not affect those of cyclin E-Cdk2, cyclin A-Cdk2 or cyclin B-Cdc2 complexes. p19 is expressed at maximal level during S phase, while overexpression of p19 leads to G1 arrest.
Alternative Name:
Cyclin-dependent kinase 4 inhibitor D, p19-INK4d, CDKN2D
Application Dilution: WB: 1:500~1:2000, IF: 1:50~1:200
Specificity: CDKN2D polyclonal antibody detects endogenous levels of CDKN2D protein.
Immunogen:
Recombinant full length Human CDKN2D.
MW: ~ 18 kDa
Swis Prot.: P55273
Purification & Purity:
The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen and the purity is > 95% (by SDS-PAGE).
Format:
1mg/ml in PBS with 0.1% Sodium Azide, 50% Glycerol.
Storage:
Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze-thaw cycles.
For research use only, not for use in diagnostic procedure.
| Is Featured? | No |
|---|
Write Your Own Review